OBJECTIVE: To evaluate potentially inappropriate medication among hospitalized older patients. METHODS: A total of 426 inpatients aged 60 s years old were included in study. The incidence of potentially inappropriate medication was defined on the basis of Beers Criteria (2003 edition). RESULTS: 426 inpatients whose mean ages were 74.8 years old took 8 kinds of medicine per patient. Our study revealed that 58 cases (13.6%) of potentially inappropriate medication were associated with drugs; 47 cases (11.0%) were dependent on disease or condition. CONCLUSIONS: A high prevalence of potentially inappropriate medication in hospitalized older patients requires further steps to prevent its occurrence.

Objective To summarize the clinical medicine treatment in elderly patients with renal dysfunction,in order to discover the existing problems and analyze the reasons.Methods One hundred and eighty cases of senile patients with renal insufficiency were randomly selected in the second half of 2012 to analyze medication states based on the medication standard.Results Medical advices prescribed by doctors showed that 7.5 ％ of drugs were forbidden used in patients with severe renal insufficiency,and 34.1％ of drugs should be used with caution or reduction requirements.Each department and system had irrational drug using.Conclusions There are a large problem in the clinical medication in patients with renal insufficiency,and a reasonable medication standard needs to be established to find out potential irrational drug using so as to reduce the possibility of adverse reactions.

Objective: To explore the anti-proliferation and apoptosis-inducing effects of decitabine combined with paclitaxel on paclitaxel-resistant MCF-7 cells. Methods:Cell counting kit-8 (CCK-8) assays were used to determine the proliferation inhibition of drugs at different concentrations in 24, 48 and 72h. The group was treated with decitabine, paclitaxel and the combination of the two drugs, respectively. The cell apoptosis rate was determined by flow cytometry after the treatment with the drugs at different concentra-tions in 48h. Results:The results of CCK-8 showed the combination group significantly inhibited the cell proliferation when compared with the single drug use group(P<0. 05), and the anti-proliferation value was in a dose-dependent manner in all groups. The apopto-sis values after the treatment with decitabine, paclitaxel and the combination in 48h was(20. 4 ± 1. 98)%,(21. 8 ± 3. 34)% and(70. 8 ± 8. 23)%,respectively. Conclusion:The proliferation inhibition and apoptosis induction are both increased significantly in the com-bination group. Synergistic effect of decitabine and paclitaxel is found in multidrug resistant breast cancer cell line MCF-7 in vitro.

Objective To establish the drug use evaluation ( DUE) of Dolasetron, evaluate the rationality of the clinical use of Dolasetron and provide a reference for the rationally clinical use of Dolasetron．Methods On the basis of Dolasetron DUE criteria, a retrospective analysis was made in 794 hospitalized patients from January 2021 to June 2021. Results The drug use evaluation criterion on Dolasetron consisted of drug indications, drug use process, the result of drug use and indication management. Conclusion There are some inappropriate medication problems in Dolasetron utilization in the hospital. The DUE criterion is very practical which could be used to standardize the clinical utilization of Dolasetron.